Everything below concerns GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-15. Numbers and descriptions here follow the published literature rather than marketing material.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
==== Corporate developments and acquisitions ==== In September 2020, the company acquired a 9.9% stake in CStone Pharmaceuticals for $200 million (HK$1.55 billion), helping to commercialise its anti-PD-L1 monoclonal antibody, CS1001. In October 2020, the company acquired Arixa Pharmaceuticals. In November 2020, using a Reverse Morris Trust structure, Pfizer merged its off-patent branded and generic drug business, known as Upjohn, with Mylan to form Viatris, owned 57% by Pfizer shareholders. On January 5, 2021, Pfizer introduced a new logo. In April 2021, Pfizer acquired Amplyx Pharmaceuticals and its anti-fungal compound fosmanogepix (APX001). In August, the company announced it would acquire Trillium Therapeutics Inc and its immuno-oncology portfolio for $2.3 billion. In November 2021, gene therapy research was delayed by trial changes. In March 2022, the company acquired Arena Pharmaceuticals for $6.7 billion in cash. In June 2022, the company acquired ReViral Ltd, for up to $525 million, gaining access to experimental drugs used to combat respiratory syncytial virus infections. In October 2022, the company acquired Biohaven Pharma and its calcitonin gene-related peptide programs for $11.6 billion. It also acquired Global Blood Therapeutics for $5.4 billion, boosting Pfizer's rare disease business. In April 2023, Pfizer moved its world headquarters from 42nd Street in Midtown Manhattan to the Spiral at Hudson Yards. In September 2023, CDC Endorsed Pfizer's Maternal RSV Vaccine to Shield Newborns.
=== Early political career === According to Lad's published biography, he began his political career through the Sandur municipal council in 2002. He contested the 2004 Karnataka Legislative Assembly election from the Sandur constituency as a candidate of the Janata Dal (Secular). He defeated Congress candidate V. Y. Ghorpade, receiving 65,600 votes against Ghorpade's 30,022, a margin of 35,578 votes. Lad subsequently joined the Indian National Congress in 2007.
=== Dextran microspheres === Dextran can be used as a standalone material in microspheres. Dextran microspheres can provide controlled drug release in gastric and intestinal pH environments, which is ideal for targeting of the colon.
National Security Council spokesman John Kirby responded by accusing Lula of "parroting Russian and Chinese propaganda", describing his comments as "simply misguided" and "suggesting the United States and Europe are somehow not interested in peace, or that we share responsibility for the war." On 19 May 2023, Lula said he was "upset" after Ukrainian president Volodymyr Zelesnkyy did not attend a meeting between both on the sidelines of the G7 Summit in Hiroshima. On 22 May, Danish foreign minister Lars Løkke Rasmussen said that Denmark was interested in hosting a summit aimed at "finding peace between Ukraine and Russia". but "it is necessary to build interest and involvement from countries like India, Brazil and China." In September 2023, Lula and Ukrainian president Volodymyr Zelenskyy met on the sidelines of the 78th United National General Assembly (UNGA), in New York; Lula pledged to maintain an open dialogue between their countries to end the war.
Sources: en.wikipedia.org
== Organization == The Union's leadership centered on Boris Savinkov, who directed its political and military activities and maintained contact with anti-Bolshevik allies and foreign representatives. Among the organization's known personnel were:
== First Ministry == The Governor, Ken Michael, designated 14 principal executive offices of the Government under section 43(2) of the Constitution Acts Amendment Act 1899. The following ministers and parliamentary secretaries were then appointed to the positions, and served until the reconstitution of the Ministry on 10 March 2005. The list below is ordered by decreasing seniority within the Cabinet, as indicated by the Government Gazette and the Hansard index.
Glutathione + Isopentenyl Pyrophosphate → 3-MBG 3-MBG + γ-GTP → MBCG MBCG + Cauxin → Felinine + Glycine, or MBCG → N-Acetylfelinine Urine of domestic cats may contain a series of felinine-containing compounds including free felinine, acetylfelinine, felinylglycine and 3-MBG. Cysteine also plays a role in the synthesis of felinine. For one, the amino acid is commonly present in many enzymes. Also, it is one of the few precursors for glutathione. Glutathione is converted to 3-MBG, and so cysteine has an important role in the early steps of synthesis.
=== Translation initiation === Protein synthesis is primarily regulated at the stage of translation initiation. In eukaryotes, the canonical initiation pathway requires at least 12 protein initiation factors, some of which are themselves large complexes. The structures of the 40S:eIF1 and 60S:eIF6 complexes provide first detailed insights into the atomic interactions between the eukaryotic ribosome and regulatory factors. eIF1 is involved in start codon selection, and eIF6 sterically precludes the joining of subunits. However, structural information on the eukaryotic initiation factors and their interactions with the ribosome is limited and largely derived from homology models or low-resolution analyses. Elucidation of the interactions between the eukaryotic ribosome and initiation factors at an atomic level is essential for a mechanistic understanding of the regulatory processes, but represents a significant technical challenge, because of the inherent dynamics and flexibility of the initiation complexes. The first structure of the mammalian pre initiation complex was done by cryo-electron microscopy. Other structures of initiation complexes followed soon, driven by cryo-EM technical improvements. Those structures will help better understand the process of translation initiation in eukaryotes.
He also opposes the Trans-Pacific Partnership, which he says was "written by corporate America and the pharmaceutical industry and Wall Street." On May 1, 2019, he tweeted: "Since the China trade deal I voted against, America has lost over three million manufacturing jobs. It's wrong to pretend that China isn't one of our major economic competitors." Sanders also strongly opposes outsourcing American jobs. During discussions of the United States Innovation and Competition Act, which was to be used to fund the manufacture of semiconductors amid a shortage, he proposed a measure to ensure the companies the bill funded could not outsource their jobs. The proposed measure would also block the companies from forbidding their employees to unionize. Sanders's proposal was voted down by most Democrats and all Republicans in the Senate. Ahead of the 2022 midterms, Sanders said he wants the Democratic Party to focus more on supporting unionization: "I think we should move to a system where, if 50% of the workers in a bargaining unit plus one vote to form a union, they have a union.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.